Sy Mukherjee, Fortune

Sy Mukherjee


New York, NY, United States

Contact Sy

Discover and connect with journalists and influencers around the world, save time on email research, monitor the news, and more.

Start free trial

  • Fortune

Recent articles by Sy:

Bristol-Myers Squibb Loses $6 Billion in Value on Celgene Deal Setback: Brainstorm Health

Bristol Myers surprised investors, announcing it would spin off Celgene's popular drug Otezla to address antitrust concerns. → Read More

Digital Health Companies Hit a New VC Funding Record in 2018

Health care is headed for the cloud. Digital health tech investment is nearing the moon. → Read More

About That 'Cell Phones Give You Horns' Study: Brainstorm Health

Let's not slap the "horns" warning on smartphones quite yet. → Read More

Google, Pharma Giant Sanofi Team Up to Discover Drugs: Brainstorm Health

Happy hump day, readers. Another big pharma company is seeking reinvention in the digital era. This time around, it’s Sanofi, the French drug mainstay long known for its insulin and diabetes portfolio – but which has faced mounting pressures in a crowded field choc full of competitors. Now, Sanofi and Alphabet’s Google are teaming up to use data collection and artificial intelligence in a bid to… → Read More

The Kids Are Not All Right: Brainstorm Health

Good afternoon, readers. Suicide has been on the rise in America in recent years. And a new report suggests the trend has hit teenagers especially hard. Harvard Medical School and Tel Aviv University researchers found that “adolescents are of particular concern” when it comes to the 30% spike in American suicides between 2000 and 2016, “with increases in social media use, anxiety, depression,… → Read More

Exclusive: P&G, Huffington's Thrive Global Team Up to Turn Everyday Products Into Wellness Boosters

The behavioral health partnership is linked to some of P&G's common consumer health products. → Read More

How P&G and Thrive Global Want Everyday Products to Make You Feel Good About Yourself: Brainstorm Health

Arianna Huffington's Thrive Global struck a wellness-boosting initiative featuring common Procter & Gamble products. → Read More

Big Drug Makers Sue to Block Mandatory Price Disclosures in TV Ads: Brainstorm Health

Amgen, Merck, Eli Lilly, and others sued to block the Trump administration's proposed rule on drug TV ads. → Read More

The NIH Chief Wants to End the 'Manel'—Brainstorm Health

NIH director Francis Collins is cracking down on all-male panels in a bid for equality in the life sciences. → Read More

The Ideal Diet That Doesn't Exist: Brainstorm Health

Happy Monday, readers. I hope you had a wonderful weekend. First off, a hearty thanks to all of you have already reached out with recommendations for Fortune‘s latest Change the World list. Please keep them coming! You may noticed just how much digital space is consumed by nutrition and diet stories. Perhaps that’s not much of a surprise – the health and wellness industries have effective (and… → Read More

Help Us Find the Companies Changing the World: Brainstorm Health

Help us find the companies changing the world. → Read More

The Ethics of 'Biohacking' and Digital Health Data: Brainstorm Health

An expert panel discusses what we need to do to make digital health data collection ethical. → Read More

From Pokemon Go to... Pokemon Sleep?—Brainstorm Health

The Pokemon Go makers are getting in on the rest and wellness game. → Read More

How This Biotech Wants to Become a Stem Cell Therapy Success Story

Athersys is trying to succeed where many other biotechs have failed: The stem cell therapy industry. Here's why they think they can. → Read More

Brainstorm Health: Amarin Stock, Oklahoma Opioid Testimony, Work Burnout

Good afternoon, readers. All aboard the fish train! On Wednesday, shares of biotech Amarin shot up more than 11% after the company got another piece of good news in what’s been (so far) a fortuitous 2019 – a Food and Drug Administration (FDA) priority review for its prescription strength fish oil pill Vascepa. Amarin’s stock is now up a relatively modest 6% on the year after a bit of a… → Read More

Brainstorm Health: Athersys Stem Cell Treatment, Alexa in Medicine, Oklahoma Opioid Suit

Happy Tuesday, readers! I hope you had a wonderful long weekend. The world of stem cell-based medicine has had its fair share of disappointments and regulatory recriminations over wildly inflated claims. But Athersys CEO Gil Van Bokkelen says the stem cell field isn’t getting a fair shake. “It’s a misconception to say stem cells haven’t really delivered,” he tells Fortune in an interview. “This… → Read More

Brainstorm Health: Novartis $2.1 Million Drug, Brexit Fallout, Jakafi Drug Approval

Happy Friday, readers! On Friday, drug giant Novartis got the Food and Drug Administration (FDA) green light for a first-of-its-kind gene therapy to treat a rare, devastating genetic muscle-wasting disorder called spinal muscular atrophy (SMA). This victory was largely expected; all eyes, however, were on where Novartis would place the treatment’s list price. Speculation was rampant. Would it be… → Read More

Brainstorm Health: Heart Disease, Amazon Emotion Detection, JPMorgan and Purdue

Good afternoon. I have some good news and some, well, not-great news. Cancer deaths in the U.S. fell sharply – and I mean really sharply – between 1999 and 2017 among 45 to-64 year-old Americans, according to a new Centers for Disease Control (CDC) report. But deaths attributable to heart disease have risen in recent years among this same cohort. Heart disease accounts for a staggering one in… → Read More

Brainstorm Health: CRISPR V. Superbugs, Gottlieb to NEA, UniQure Gene Therapy

Hello and happy hump day, readers! Former Food and Drug Administration (FDA) Commissioner Scott Gottlieb already has a new gig. Gottlieb unexpectedly departed from his position as the country’s top drug regulator earlier this year, citing personal reasons and a wish to spend more time with his family. The surprise move came after a brief tenure that was, nonetheless, lauded by a surprising… → Read More

Brainstorm Health: Verily Pharma Partners, 'Conscience' Clause Lawsuits, Merck's Mulligan

Good afternoon, readers. I read something pretty troubling (if not surprising) this morning. And, yes, it has to do with my generation, AKA the millennial folk. You may have heard that American health care is an unadulterated mess, and that messiness forces millions of people to make tough decisions when it comes to their finances. Millennials are no exception to that dilemma, according to new… → Read More